The new international collaboration will bring together experts in medicine, drug discovery and artificial intelligence with the aim of finding new treatments for common diseases as well as rare genetic conditions. There will be a dedicated leadership team at each institution; at Oxford, it will be overseen by the Centre for Medicines Discovery (CMD) in the Nuffield Department of Medicine.
Over the next five years, this international collaboration hopes to develop new drug targets, as well as create new platforms and technologies to aid drug discovery. Education will also be a key component of the partnership, including welcoming students from Saudi Arabia.
The first programme of research will be on AI-guided drug discovery for rare and cardio-metabolic diseases, conducted by scientists from CMD, the Department of Psychiatry, the Department of Statistics and the Nuffield Department of Population Health at Oxford, and researchers from KAU.